Ucan Gunduz, G. Et Al. 2021. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS , vol.37, no.4 , 236-240.

Ucan Gunduz, G., Yalcinbayir, Ö., Cekic, Ş., Yildiz, M., & Kilic, S. Ş., (2021). Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS , vol.37, no.4, 236-240.

Ucan Gunduz, Gamze Et Al. "Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab," JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS , vol.37, no.4, 236-240, 2021

Ucan Gunduz, Gamze U. Et Al. "Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab." JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS , vol.37, no.4, pp.236-240, 2021

Ucan Gunduz, G. Et Al. (2021) . "Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab." JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS , vol.37, no.4, pp.236-240.

@article{article, author={Gamze Ucan Gunduz Et Al. }, title={Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab}, journal={JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS}, year=2021, pages={236-240} }